Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse
- 15 December 1989
- Vol. 64 (12), 2448-2458
- https://doi.org/10.1002/1097-0142(19891215)64:12<2448::aid-cncr2820641209>3.0.co;2-7
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Effect of Granulocyte Colony-Stimulating Factor on Neutropenia and Associated Morbidity Due to Chemotherapy for Transitional-Cell Carcinoma of the UrotheliumThe New England Journal of Medicine, 1988
- M-Vac (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Advanced Transitional Cell Carcinoma of the UrotheliumJournal of Urology, 1988
- Neoadjuvant M-Vac (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) Effect on the Primary Bladder LesionJournal of Urology, 1988
- Chemotherapy of urothelial tract tumorsCancer, 1987
- Combination Chemotherapy with Cisplatin and Methotrexate in Advanced Transitional Cell Cancer of the BladderJournal of Urology, 1987
- Caliceal Obstruction Owing to a Large Parapelvic Cyst: Excretory Urography, Ultrasound and Computerized Tomography FindingsJournal of Urology, 1987
- Regional Lymph Node Metastasis From Bladder CancerJournal of Urology, 1981
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958